Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.

The EMBO journal - 1 Oct 2025

Lai Chun-Fui, Cushing Victoria I, Olden Ellen, Bevan Charlotte L, Coombes R Charles, Greber Basil J, Buluwela Laki, Ali Simak

Abstract excerpt

CDK7 has emerged as a cancer target because of its pivotal roles in cell cycle progression and transcription. Several CDK7 inhibitors (CDK7i) are now in clinical evaluation. Identifying patients most likely to respond to treatment and early detection of tumour evolution towards resistance are necessary for optimal implementation of cancer therapies. Continuous culturing of prostate cancer cells with Samuraciclib,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cryoelectron Microscopy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinases

Share to Drug Resistance, Neoplasm

Share to CDK4 gene

Share to Mutation

Share to Prostatic Neoplasms

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 40921851
DOI: 10.1038/s44318-025-00554-6
PMCID: PMC12528448

Genes

CDK7
CDK12
CDK4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.PMID 40921851Read ↗

Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell deathSemantic proximity Read ↗

CDK7 inhibitors as anticancer drugsSemantic proximity Read ↗

Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors.Semantic proximity Read ↗

A general framework for inhibitor resistance in protein kinases.Semantic proximity Read ↗

A cancer-derived mutation in the PSTAIRE helix of cyclin-dependent kinase 2 alters the stability of cyclin binding.Semantic proximity Read ↗

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?Semantic proximity Read ↗

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase InhibitorsSemantic proximity Read ↗

Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitorsSemantic proximity Read ↗

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibitionSemantic proximity Read ↗

Analysing the Effect of Mutation on Protein Function and Discovering Potential Inhibitors of CDK4: Molecular Modelling and Dynamics Studies.Semantic proximity Read ↗

Structural insights into the mechanism of resistance to bicalutamide by the clinical mutations in androgen receptor in chemo-treatment resistant prostate cancer.Semantic proximity Read ↗

Functional characterization of the human Cdk10/Cyclin Q complexSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.